REGENERON PHARMACEUTICALS, INC. — Director's Dealing 2012

Aug 30, 2012

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: REGENERON PHARMACEUTICALS INC (REGN)
CIK: 0000872589
Period of Report: 2012-08-28

Reporting Person: STAHL NEIL (SVP Research and Development S)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2012-08-28	Common Stock	M	40000.0	$21.92	Acquired	99121.0	Direct
2012-08-28	Common Stock	F	6017.0	$145.7	Disposed	93104.0	Direct
2012-08-28	Common Stock	F	17099.0	$145.7	Disposed	76005.0	Direct
2012-08-29	Common Stock	S	1500.0	$144.92	Disposed	74505.0	Direct
2012-08-29	Common Stock	S	9386.0	$145.44	Disposed	65119.0	Direct
2012-08-29	Common Stock	S	5998.0	$146.41	Disposed	59121.0	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2012-08-28	Non-Qualified Stock Option (right to buy)	$21.92	M	40000.0	Disposed	2017-12-17	Common Stock (40000.0)	Direct
2012-08-28	Non-Qualified Stock Option (right to buy)	$145.7	A	6017.0	Acquired	2017-12-17	Common Stock (6017.0)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	5479.0	Indirect

Footnotes

F1: Represents volume-weighted average price of sales of 1,500 shares of Company stock on August 29, 2012 at prices ranging from $144.82 to $144.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 29, 2012 at each separate price.

F2: Represents volume-weighted average price of sales of 9,386 shares of Company stock on August 29, 2012 at prices ranging from $145.04 to $145.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 29, 2012 at each separate price.

F3: Represents volume-weighted average price of sales of 5,998 shares of Company stock on August 29, 2012 at prices ranging from $146.01 to $146.93. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 29, 2012 at each separate price.

F4: The stock option award (combined incentive stock option and non-qualified stock option) vests in four equal annual installments, commencing one year after the date of grant.

F5: Exercisable date, exercise date, exercise price, purchase price, sales price, and/or expiration date is/are not applicable in this case.